Literature DB >> 8067765

Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.

M Opravil1, B Joos, R Lüthy.   

Abstract

Concentrations of dapsone, monoacetyldapsone, and pyrimethamine were determined in 36 serum samples from human immunodeficiency virus-infected patients on prophylaxis with once-weekly administration of dapsone-pyrimethamine (200 mg of dapsone-75 mg of pyrimethamine). During day 1 after ingestion, median levels of 1,038 ng of dapsone per ml and 356 ng of pyrimethamine per ml were found. During days 6 to 7, the dapsone level fell to < 20 ng/ml in five of nine serum samples, but the pyrimethamine level remained elevated (125 ng/ml). Concurrent, but separately ingested, didanosine administration did not seem to decrease the drug concentrations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067765      PMCID: PMC188179          DOI: 10.1128/AAC.38.5.1197

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Failure of prophylaxis with dapsone in patients taking dideoxyinosine.

Authors:  C E Metroka; M F McMechan; R Andrada; L J Laubenstein; D P Jacobus
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

2.  Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.

Authors:  L M Weiss; C Harris; M Berger; H B Tanowitz; M Wittner
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

3.  Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions.

Authors:  B L Lee; I Medina; N L Benowitz; P Jacob; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1989-04-15       Impact factor: 25.391

4.  Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim.

Authors:  C R Jones; S M Ovenell
Journal:  J Chromatogr       Date:  1979-06-11

5.  Quantification of antimalarial drugs. II. Simultaneous measurement of dapsone, monoacetyldapsone and pyrimethamine in human plasma.

Authors:  M Edstein
Journal:  J Chromatogr       Date:  1984-05-11

Review 6.  Clinical pharmacokinetics of dapsone.

Authors:  J Zuidema; E S Hilbers-Modderman; F W Merkus
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.

Authors:  M C Broughton; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Simultaneous estimation of serum concentrations of dapsone, monoacetyldapsone, and pyrimethamine in Chinese men on maloprim for malaria prophylaxis using reversed-phase high performance liquid chromatography.

Authors:  H S Lee; T Y Ti; P S Lee; C L Yap
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

9.  Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.

Authors:  M T Cushion; D Stanforth; M J Linke; P D Walzer
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

10.  Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.

Authors:  C J Allegra; J A Kovacs; J C Drake; J C Swan; B A Chabner; H Masur
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients.

Authors:  M Cruciani; G Gatti; C Mengoli; A Cazzadori; L Lazzarini; F Miletich; M S Graziani; M Malena; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex.

Authors:  L M Shah; S C Meyer; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  Drug interactions with antiviral drugs.

Authors:  A M Taburet; E Singlas
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

5.  Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.

Authors:  K W Henry; M C Cruz; S K Katiyar; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.

Authors:  G Gatti; M Merighi; J Hossein; S Travaini; R Casazza; M Karlsson; M Cruciani; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.

Authors:  H Klinker; P Langmann; E Richter
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

8.  Pharmacokinetics of dapsone in human immunodeficiency virus-infected children.

Authors:  G Gatti; A Loy; R Casazza; F Miletich; M Cruciani; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

9.  Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors:  R E Kast
Journal:  Springerplus       Date:  2015-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.